

In the claims:

Claim 1, line 3, please change "microliter" to --microliters--; and

Claim 4, line 6, please change "Parenterally" to --parenterally--.

REMARKS

Claims 1-4 are now pending. Reconsideration of these claims is respectfully requested in view of the above amendment and the following remarks.

Objections to the specification and claims

The Examiner objects the specification and claims 1 and 4 because of the informalities. The specification and claims have been amended to eliminate those informalities as shown in the above amendment. Accordingly, objections to the specification and claims have been overcome.

Rejection under 35 U.S.C. 112, second paragraph

The Examiner rejects claims 1-4 under 35 U.S.C. 112, second paragraph, as failing to set forth the subject matter which applicant regards as his invention on the ground that the claims fail to correspond in scope with that which applicants allegedly regard as the invention as filed, i.e. the co-administration of prednisone with the Product R. However, the present invention is mainly directed to a method of treating an autoimmune disease, namely, rheumatoid arthritis, by administrating Product R to the patient, not by the combination of Product R with prednisone.

Apparently, the statement "Prednisone is co-administered with Product R" in the section "Summary of the Invention" is apparently an error, since the invention as claimed does not require prednisone to be co-administered with Product R.

Although the Examiner argues that the present invention encompasses only the co-administration of Product R with prednisone by pointing out another statement in the application, i.e., "Prednisone is co-administered with Product R to provide a combined therapy in treating autoimmune diseases" (page 13, lines 16-17), the specification, as a whole, reads differently. Specifically, the specification unequivocally states that "Product R may be administered alone or together with an autoimmune disease treatment agent". Spec. p12, ll 9-10. Moreover, the clinical trial described in the specification was evidently based on the administration of Product R alone. Spec. pp 14-20. Thus, the claimed invention is fully supported by the specification.

The Examiner also rejects claims 1-4 under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention on the ground that the metes and bounds of the claim language "effective symptom ameliorating amount" in claims 1 and 4 are unclear. Applicant respectfully traverses the Examiner's position.

First, the metes and bounds of the phrase "effective symptom ameliorating amount" are clearly set forth in claim 1 by reciting the exact amount of Product R that is "in a range from about 2.5 microliters to about 40 microliters per kilogram of body weight per day"; and in claim 4 by reciting an amount of about 1ml per patient twice per day. A person of ordinary skill in the art can readily determine proper dosages of Product R to be given to each

patient per day either based on the patient's body weight or merely by merely following the recitation of the claim.

Second, there is no discrepancy between the two described methods of making Product R. The two methods for making Product R differs only in that Method I uses NaOH to completely digest RNA while Method II uses HCl to achieve the same outcome. Since the two resulting products are the same, they must also have the same levels of activity.

It should be noted that Product R produced by Methods I or II is the drug itself in a liquid form. It is not further formulated and is measured by volume in the same sense as a solid drug that is measured by weight. Thus, the volume to be administered is the active units present in that volume.

Accordingly, applicant respectfully submits that rejection under 35 U.S.C. 112, second paragraph, has been overcome and should be withdrawn.

Rejection under 35 U.S.C. 102

The Examiner rejects claims 1-4 under 35 U.S.C. 102(e) as being anticipated by Kochel (U.S. Pat. No. 5,849,196).

However, Kochel' patent is irrelevant to the present application because the manufacture and composition of Kochel's product are significantly different from Product R. As indicated in the present application, "[p]roduct R is a refinement of RETICULOSE prepared by an improved manufacturing process. Spec. P7, ll 10-11. Detailed analysis on the manufacture process and composition of Product R has been set forth in U.S. patent application Serial Number 09/344,095, a copy of which is attached herewith. Specifically, a comparison between the conventional composition of RETICULOSE used in the Kochel' patent

and Product R is set forth from pages 21 to 2 with respect to their molecular weight distribution, ultraviolet absorbancies and certain biological function are shown, indicating that the conventional RETICULOSE and Product R are two different products.

Since Kochel's patent is irrelevant to the present invention, applicant respectfully submits that Kochel's patent should be removed as a 102(e) prior art reference and rejection under 35 U.S.C. 102(e) should be withdrawn.

Rejection under 35 U.S.C. 103

The Examiner rejects claims 1-4 under 35 U.S.C. 103(a) as being obvious over Kochel (U.S. patent 5,849,196) in view of Lapin (U.S. patent 4,743,596).


As discussed above, the Kochel's patent is irrelevant to the present invention. Accordingly, rejection under 35 U.S.C. 103(a) should be withdrawn.

In view of the above remarks, allowance of claims 1-4 is respectfully requested.

It is believed that no fees or charges are required at this time in connection with the present application; however, if any fees or charges are required at this time, they may be charged to our Patent and Trademark Office Deposit Account No. 03-2412.

Respectfully submitted,
COHEN, PONTANI, LIEBERMAN & PAVANE

By



Myron Cohen

Reg. No. 17,358

551 Fifth Avenue, Suite 1210
New York, New York 10176
(212) 687-2770

Dated: June 29, 2000

09344095



By Express Mail # EL370001350US

APPLICATION FOR UNITED STATES
LETTERS PATENT

PREPARATION OF A THERAPEUTIC COMPOSITION

Inventor(s):

Bernard FRIEDLAND
Shalom Z. HIRSCHMAN

D. S. 1/2

RELATED APPLICATIONS

This is a continuation-in-part application of the applicant's pending-application
Serial Number 08/735,236, filed on October 22, 1996.^{now abandoned} This application incorporates contents
of the application Serial Number 08/735,236 by reference in their entirety.

W.L. [initials]

BACKGROUND OF THE INVENTION

OK to
enter
US
11/15/04

1. Field of the Invention

The present invention relates to an improved method of making a therapeutic composition, Product R¹, as hereinafter defined, which contains peptides and nucleotides. The components of Product R have molecular weights not more than 14 kilodaltons (KDa).

5
2. Description of the Related Art

The concept of an antiviral agent composed of peptones, peptides, proteins and nucleic acid was originated in 1934. After some years of experimentation, such an antiviral agent 10 was modified by using bovine serum albumin in combination with peptone, and ribonucleic acid to produce an antiviral biotic agent which is nontoxic, free from anaphylactogenic properties and is miscible with tissue fluids and blood sera. The agent used to be described as a "lipopeptide-nucleic acid compound"² and registered under trademark RETICULOSE® by Chemico Laboratories, Inc. Physician Desk Reference, p 651, 1960. RETICULOSE® was reported as an 15 antiviral agent for treating a variety of human viral infections, such as influenza, herpes, hepatitis A and B. It was then assumed that RETICULOSE® acts as an antiviral agent at least by increasing leukogenesis, synthesis of antibodies and enhancing phagocytosis. RETICULOSE® was last sold in the United States in 1964.

¹ Product R was used as synonyms of RETICULOSE in some literature. For the purpose of the present application, Product R and RETICULOSE represent two distinct products.

The method of making RETICULOSE® had been kept as a trade secret by the manufacturer until the issuance of U.S. patent 5,849,196, which discloses the method of making RETICULOSE®.

As disclosed in U.S. patent 5,849,196, the starting materials for making RETICULOSE® consist of, by weight, 40-50 % of casein, 1-10 % of blood albumin, 15-40 % of beef peptone, 10-25 % of RNA and 5-25 % of sodium hydroxide. These starting materials are suspended in water which yields a ratio of proteins (casein, peptone and blood albumin) to water equals to about 4.3 to about 100 by weight. After an autoclaving treatment of the mixture of the starting materials, the resulting solution is filtered and pH is adjusted to approximately 8.5 and then to 7.8, after which the neutralized solution is filtered again. The pH is further adjusted to approximately 7.5 after the solution is diluted. Such process yields a mixture of peptides and nucleic acids having molecular weights in a range of approximately 1 to 25 KDa.

As taught by U.S. patent 5,849,196, the components over 15 KDa of the conventional composition of RETICULOSE® are more effective in treating viral diseases such as HIV, influenza virus, herpes simplex virus, etc. while the components in a range of approximately 1 to 15 KDa function as phagocytosis inhibitors.

However, the conventional methods suffers from several disadvantages: 1) the method does not ensure that each preparation produces the finished components having the same ratio, thereby the product is not reproducible; 2) the conventional method produces a wide range of the finished components, which makes the quality control of the preparation extremely difficult, if possible, because too many parameters need to be determined; 3) the presence of the

higher molecular weight components, such as 25 KDa component, essentially peptides, increases the risk of hypersensitivity or immune reaction and renders the product less stable.

Therefore, it is desirable to have a product devoid of the deficiencies of conventional RETICULOSE® while maintaining its therapeutic properties.

SUMMARY OF THE INVENTION

Accordingly, an object of the present invention is directed to a novel therapeutic composition, Product R. Unlike RETICULOSE®, Product R is reproducible, highly stable and non-antigenic. Similar to RETICULOSE®, Product R is a wide range antiviral agent for treating 5 viral infections such as infections of human immunodeficiency virus (HIV), herpes simplex virus, adenovirus and papilloma virus. Surprisingly, Product R has been proven to be effective in stimulating the production of chemokines including interferon-gamma, interleukin-6 and interleukin-1 (J. Investig Med 1996; 44:347-351), the production of red blood cells (U.S. Patent No. 5,807,839), treating basal cell carcinoma (U.S. Patent No. 5,902,786) and treating canine 10 distemper viral infections (U.S. Patent No. 5,807,840).

Another object of the present invention is directed to an improved method for making the novel therapeutic composition Product R. Product R according to the present improved method comprises novel components that generate a novel UV absorption spectrum and a novel molecular weight profile. Particularly, Product R comprises molecules having molecular 15 weights not more than 14 KDa.

A further object of the present invention is to define the components of Product R based on chemical and physical methods.

Other objects and features of the present invention will become apparent from the following detailed description considered in conjunction with the accompanying drawings.

20 It is to be understood, however, that the drawings are designed solely for purposes of illustration and not as a definition of the limits of the invention, for which reference should be

By Express Mail # EL370001350US

made to the appended claims. It should be further understood that the drawings are not necessarily drawn to scale and that, unless otherwise indicated, they are merely intended to conceptually illustrate the structures and procedures described herein.

BRIEF DESCRIPTION OF THE DRAWINGS

In the drawings:

Figure 1 shows a representative ultraviolet absorption profile of Product R;

Figure 2 shows a representative chromatogram of Product R obtained from a
5 reverse phase HPLC analysis;

Figure 3 shows a BioGel P-2 fractionation profile of Product R;

Figure 4 shows the components of fraction I of the BioGel P-2 fractionation profile
resolved on a 16% SDS-Polyacrylamide gel electrophoresis (SDS-PAGE);

10 Figure 5 shows the relative mass (Mr.) of the two major peptide components of
Product R resolved on a 16% SDS-PAGE;

Figure 6 is a 16% SDS-PAGE, showing the effects of a variety of catabolic
enzymes on Product R;

Figure 7 is a flow cytometric histograms, showing the effect of Product R on
phagocytosis of Dextran-FITC; and

15 Figure 8 is a flow cytometric histograms, showing the effect of Product R on
phagocytosis of Dextran-BoDipyFL.

DETAILED DESCRIPTION OF THE PRESENTLY PREFERRED EMBODIMENTS

Preparation of Product R

Generally, Product R is prepared according to the following manner.

First, the starting materials casein, beef peptone, RNA, BSA, and sodium hydroxide are suspended in proportions of, by weight, 35-50% (casein), 15-40% (beef peptone), 5 10-25% (RNA), 1-10% (BSA) and 5-25% (sodium hydroxide) in an appropriate volume of distilled water. All starting materials are generally available or otherwise can be readily prepared by a person of ordinary skill in the art. While any RNA is suitable for the intended purpose of the present invention, plant RNA is preferred and yeast RNA is the most preferred. The ratio of total 10 proteins versus the volume of distilled water is generally about 1.5-2.5 to about 100 by weight, preferably about 2.2 to about 100 by weight. This means that every 1.5-2.5 grams of the total proteins are suspended in about 100 milliliters of distilled water.

All the starting materials are either generally commercially available or can be readily prepared by a person of ordinary skill in the art.

15 The suspension as prepared above is then autoclaved at a pressure of approximately 5-15 lbs., preferably 8-10 lbs. under an elevated temperature in a range, for example about 150 - 300 °F, preferably about 200-230 °F, over a period of approximately 2-10 hours, preferably more than 3 hours. As known to a person of ordinary skill in the art, under such conditions RNA may be completely hydrolyzed into nucleotides. After autoclaving, the solution is 20 cooled down to room temperature, and then allowed to stay at a temperature of 3 to 8 °C for at

least 12 hours to precipitate insoluble elements. Alternatively, the cooled solution may be centrifuged at a temperature below 8 °C to remove the precipitates.

5 The resulting solution is then filtered through a 2 micron and a 0.45 micron filters under an inert gas such as nitrogen or argon at a pressure of about 1-6 psi. In a similar manner the solution is filtered again through a pyrogen retention filter, preferably 0.2 micron.

After the above filtration, the solution may be cooled at 3 to 8 °C again for at least about 12 hours and filtered again in the same way as described above.

10 The resulting filtrate is then assayed for total nitrogen content using methods known to a person of ordinary skill in the art such as Kjeldahl method, J.G.C.D. Kjeldahl, Z. Anal. Chem., Vol. 22, p366 (1883), and its improvements. Based on the assay, the filtrate is then diluted with chilled distilled water to an appropriate volume having a preferred total nitrogen content ranging from 165 to 210 mg/ml.

15 The pH of the diluted solution is then adjusted with HCl to a physiologically acceptable pH, preferably to about 7.3 to 7.6, after which the diluted solution is filtered again through a 0.2 micron filter under an inert gas as described above.

Product R so produced contains essentially nucleotides, nucleosides and free nucleic acid bases of low molecular weights from a complete hydrolysis of RNA and small peptides from partial hydrolysis of the proteins. It is possible that the base hydrolysis of the proteins also produces free amino acids.

20 It is understood that the use of filtration technique is essentially to remove bacteria or other particles having similar size to or larger size than bacteria. Thus, any filter regardless its

manufacturer or material from which it is made is suitable for the intended purpose. All filters used in the present process are widely available to a person of ordinary skill in the art.

The final filtrate is then filled and sealed into appropriate vials, such as 2 ml or 10 ml glass vials under an inert gas. The filled vials are autoclaved for final sterilization, after which 5 they are ready for use.

In use, Product R is administered parenterally or topically to a patient in need as described in U.S. patents 5,807,839, 5,807,840 and 5,902,786, the contents of which are herein incorporated by reference in their entirety.

10

Characterization of Product R

The ultraviolet absorption spectrum: Figure 1 is a representative ultraviolet absorption spectrum of Product R measured in 1 cm path length quartz microcuvette (100 μ l capacity) using a Shimadzu Model UV-1201 UV-VIS Spectrophotometer. Product R was diluted with distilled water by 100 fold. The spectrum is recorded between 220-320 nm and shows 15 a maximum absorption at 260 nm and a trough at 235 nm. The ratio of the absorbance (A) at 260 nm over absorbance at 280 nm is 1.998 (\pm 10%), and A at 260 nm over A at 230 nm is 1.359 (\pm 10%).

The HPLC profile: Figure 2 is a representative chromatogram of Product R obtained from a reverse phase HPLC analysis using a Hewlett Packard 1100 HPLC system 20 (Hewlett Packard Co.) that includes a binary pump (Model G1312A), a diode array detector (Model G1315A), a column thermostat (Model G 1316A), a thermostatted autosampler (Model

G1329A), a sample thermostat and a vacuum degasser (Model G 1322A); and a stainless steel YMC-pack ODS-AQ S-5 uM column (YMC, Inc. 3223 Burnt Mill Dr., Wilmington, NC 28403) that has a size of 250 x 10 mm ID and pore size 120 Å. The mobile phase consisting of a 0.1 M acetic acid : triethylamine is prepared as follows: 6.0 ml of glacial acetic acid are dissolved in
5 1000 ml of HPLC grade water. The stirred solution of acetic acid is titrated with triethylamine to pH 4.8. The solution is allowed to equilibrate overnight at room temperature and then filtered through a 0.45 µM pore size and 52 mm diameter filter. The pH of the solution is readjusted to pH 4.8 if necessary with the addition of triethylamine prior to use. The mobile phase is degassed by the vacuum degasser built into the HPLC flow system. 8 µl of Product R sample are injected,
10 by means of an autosampler, into the column having a temperature set at 30 °C for each injection. The sample is then isocratically eluted from the column with 0.1 M acetic acid : triethylamine mobile phase (pH 4.8) at a rate of 1 ml per minute under a pump pressure of 92-102 bar. The chromatograms (UV absorbences at 260 nm) are run at 160 minutes per sample and the data are collected by the diode array detector and then analyzed using Hewlett-Packard HPLC
15 ChemStation software. Graphical plots are generated and statistical analysis is conducted using the SigmaPlot program. The reverse phase HPLC under such conditions results in 13 characteristic HPLC peaks: A, B, C, D, E, F, G, H, I, J, K, L and M, each of which has a characteristic UV absorption profile (data not shown).

The BioGel P-2 gel filtration profile: Figure 3 shows a fractionation profile
20 of Product R on a BioGel P-2 (Bio-Rad Laboratories Inc.) column having a size of 2.6 cm x 55 cm packed size. After loading of Product R to the column, the column is eluted with a 0.1X PBS,

preferably DULBECCO's PBS, free of calcium ion (Ca^{++}) and magnesium ion (Mg^{++}), at a flow rate of 0.5 milliliters per minute. 1X PBS contains 1.47 mM KH_2PO_4 , 2.67 mM KCl , 138 mM NaCl and 8.1 mM $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$. The eluent passes through a "Uvcord SII" monitor, which is attached to a REC 101 chart recorder and fitted with a 254 nm filter, and is collected at 12 minutes per fraction in a "Frac 200" fraction collector. The gel filtration chromatography under such conditions results in 9 fractions: I, Ia, II, IIa, IIb, III, IIIa, IV and IVa. Each individual peak is compared with known nucleotides, nucleosides and free nucleic acid bases eluted at the same or very close to the volumes of respective fractions as shown in TABLE I. Known compounds having comparable values are shown in Remarks column.

10

TABLE I

Peak	Experimental Value				Remarks
	λ_{max}	λ_{min}	A_{260}/A_{280}	A_{260}/A_{230}	
Peak I	~275nm	~255nm	0.976	0.300	Mostly peptides and peptide conjugates
Peak Ia	~260nm	~240nm	1.636	0.943	Nucleoprotein and peptide nucleic acid
Peak Is	~270nm	~245nm	1.258	0.939	Major component is CMP
Peak II α	~260nm	~230nm	2.893	3.12	Major components are AMP, UMP
Peak II β	~250nm	~225nm	1.509	1.988	Major component is GMP
Peak IIa	~250nm	~230nm	1.257	1.176	Mixed components
Peak IIb	~270nm	~250nm	1.142	0.941	Major component is Cytidine
Peak III	~260 nm	~230nm	2.695	3.664	Major component is Uridine
Peak IIIa	~260nm	~225nm	5.15	4.24	Major components are Uracil, Adenosine
Peak IV	~260nm	~225nm	5.406	3.892	Major component is Adenine
Peak IVa	~245nm	~225nm	1.016	1.285	Major component is Guanine

The fractions are then concentrated and analyzed by SDS-PAGE (see the following) on a 16% gel. Silver staining of the gel demonstrates that only fraction I shows essentially two major silverstainable bands having apparent molecular weights of 4.3 KDa, 5.2 KDa and a minor 7.6 KDa band as shown in Figure 4.

TABLE II shows the amino acid compositions of the 5.2 KDa and the 4.3 KDa components. Amino acid analysis of the 5.2 KDa band (sample A) and the 4.3 KDa band (sample B) was performed on a PE Bio-system 420 analyzer with automatic hydrolysis using standard pheno-iso-thiocyanite (PTIC) chemistry.

TABLE II

Amino acid	<u>Sample A (~5.2 kDa)</u> mol. %	<u>Sample B (~4.3 kDa)</u> mol. %
Aspartic acid	9.92	8.95
Glutamic acid	19.27	17.30
Serine	1.03	1.23
Glycine	5.74	13.87
Histidine	2.58	3.11
Arginine	0.69	0.52
Threonine	0.73	1.78
Alanine	5.49	8.19
Proline	13.05	15.28
Tyrosine	4.39	3.37
Valine	9.95	5.39
Methionine	2.92	2.21
Isoleucine	5.47	3.45
Leucine	10.99	4.37
Phenylalanine	3.27	1.45
Lysine	5.12	9.53

The biochemical properties of the peptides: Some biochemical properties

5 of the silverstainable peptide components of Product R are analyzed using various catabolic enzymes, as described below:

The treatment with proteinase K (ICN Biochemicals): Proteinase K is a non-specific broad spectrum protease that cleaves peptide bonds at the C-terminal of aliphatic, aromatic and hydrophobic amino acids. It may cleave all serum peptides completely at 50 µg/ml within one hour. A Product R sample is incubated in a reaction buffer having 10 mM Tris-HCl, pH 7.6; 0.5% of SDS; 1 mM CaCl₂; 100 µg/ml of proteinase K at 40 °C for 30 minutes and then subject to SDS-PAGE on a 16% gel as described above. Under such condition, the silver stain of Product R does not show significant change. However, when the amount of proteinase K is

increased to 800 µg/ml and the incubation time is extended to one hour, the 5.2 KDa band disappears but there is no obvious change of the 4.3 KDa band.

5 The treatment with trypsin (Boehringer Mannheim, USA): Trypsin is a serine protease, which specifically cleaves peptide bonds of lysine and arginine at the C-terminal at pH 7.5-9.0. A Product R sample is incubated in a reaction buffer having 100 mM Tris-HCl, pH 8.0, 0.1% SDS and 250 µg/ml of sequencing grade trypsin at 25 °C for 19 hours and then subject to SDS-PAGE on a 16% gel. While serum proteins will be broken down to peptides smaller than 4.3 KDa under such reaction conditions, none of the silverstainable components of Product R are affected by trypsin.

10 The treatment with chymotrypsin (Boehringer Mannheim, USA): Chymotrypsin is a serine protease that specifically hydrolyses the peptide bonds of tyrosine, phenylalanine and tryptophan at C-terminals. It also cleaves peptide bonds of leucine, methionine, alanine, aspartic acid and glutamic acid at C-terminals at relatively lower rates. A Product R sample is incubated in a reaction buffer containing 100 mM Tris-HCl, pH 7.6, 10 mM CaCl₂ and 250 µg/ml of 15 sequencing grade chymotrypsin at 25 °C for 19 hours and then subject to SDS-PAGE on a 16% gel. Chymotrypsin treatment significantly reduces the intensity of the 5.2 KDa and the 7.6 KDa bands but have no apparent effect on the 4.3 KDa band.

20 The treatment with pronase (Boehringer Mannheim, USA): Pronase is a non-specific protease, acts on both native and denatured proteins. It breaks down virtually all proteins into their individual amino acids. The preparation contains various types of endo-peptidases such as serine and metalloproteases, exo-peptidases such as carboxypeptidases, neutral protease and

neutral and alkaline phosphatases. A Product R sample is incubated in a reaction buffer containing 100 mM Tris-HCl, pH 7.4; 10 mM CaCl₂; 0.1% SDS and 2 mg/ml of pronase from *S. griseus* at 40 °C for 75 minutes and then subject to SDS-PAGE on a 16% gel. All silverstainable components disappear after such treatment of pronase.

5 The treatment with N-glycosidase F (Boehringer Mannheim, USA): N-glycosidase F cleaves all types of asparagine bound N-glycans provided that the amino group and the carboxyl group are present in a peptide linkage and the oligosaccharide has the minimum length of the chitobiose core unit. A Product R sample is incubated in a reaction buffer containing 0.4X Dulbecco's PBS (where 1X PBS contains 1.47 mM KH₂PO₄, 2.67 mM KCl, 138 mM NaCl and 10 8.1 mM Na₂PO₄ 7H₂O), 0.1% SDS, 0.5% NP40 and 50 units/ml of recombinant N-glycosidase F at 37 °C for 4 hours and subject to SDS-PAGE on a 16% gel. The treatment N-glycosidase F does not alter the intensity of any of Product R bands on the 16% SDS gel. The resistance to N-glycosidase F indicates the lack of asparagine bound N-glycan, which is commonly observed in glycoproteins.

15 The treatment with ribonuclease A (ICN Biochemicals, USA): Ribonuclease A is a pyrimidine specific endoribonuclease that acts on single stranded RNA. A Product R sample is incubated in a reaction buffer containing 10 mM Tris-HCl, pH 7.4, 3 mM MgCl₂, and 1 mg/ml of bovine pancreatic Ribonuclease A at 37 °C for about 1 hour and subject to SDS-PAGE on a 16% gel. Ribonuclease A does not alter the intensity of any of the Product R bands resolved by 16% 20 SDS-PAGE gel. The resistance to ribonuclease A excludes the possibility of the presence of a RNA fragment attached to the peptide.

The treatment with alkaline phosphatase (Life Technologies, USA): Calf thymus

alkaline phosphatase (CIAP) is a phosphomonoesterase that hydrolyses 5'-phosphate groups from DNA, RNA and nucleotides. A Product R sample is incubated in a reaction buffer provided by the manufacturer of the enzyme and 200 units/ml CIAP at 37 °C for about one hour and subjected to SDS-PAGE on a 16% gel. CIAP does not alter the intensity of any of the Product R bands resolved by SDS-PAGE.

A summary of the above described treatments by catabolic enzymes is provided in the following TABLE III, and the results of the treatment are shown in Figure 5, wherein "-" represents no substantial alteration of the stainable bands and "+" represents substantial alteration of the stainable bands.

TABLE III

<u>Enzyme</u>	<u>Sensitivity of the Peptide Components of Product R (SDS-PAGE)</u>		
	<u>4.3 KDa</u>	<u>5.2 KDa</u>	<u>7.6 KDa</u>
Proteinase K (100 µg/ml) (800 µg/ml)	-	+/-	?*
Trypsin (250 µg/ml)	-	-	-
Chymotrypsin (250 µg/ml)	-	+	+
Pronase (2 mg/ml)	+	+	+
N-glycosidase F (50 units/ml)	-	-	-
Ribonuclease A (1 mg/ml)	-	-	-
Alkaline Phosphatase (200 units/ml)	-	-	-

* This band is not clearly identified because of the presence of the enzyme fragments in that region.

The complexity of these enzymatic digestion patterns suggest that the peptide components of Product R may be conjugated with other molecules such as mono-nucleotides and/or carbohydrates, or intra/inter molecularly crosslinked.

RNA gel electrophoresis: Neither agarose nor polyacrylalmaide gel electrophoresis for nucleic acids generates any ethidium bromide stainable bands, indicating that there are no RNA fragments in Product R.

The effect of Product R on the phagocytosis: Figures 7 and 8 are flow cytometric histograms representing the cell-associated fluorescence, showing the effect of Product R on phagocytosis of Dextran-FITC or Dextran-BoDipyFL after 24 hours and 8 days of the Product R treatment, respectively. The effects of Product R on phagocytosis is tested using a human monocytic cell line, U937. The U937 cells are cultured in a medium having 5% of Product R, or 5% of PBS as a control, for 24 hours prior to the Dextran-FITC test, or 8 days prior to Dextran-BoBipyFl test. To measure phagocytosis, the cells are continuously fed with a phagocytic marker such as fluorescently-labeled Dextran-FITC for 5, 15, 30 and 45 minutes as indicated in Figure 5, or Dextran-BoDipyFL for 5, 15, 25 and 40 minutes as indicated in Figure 6 at 37 °C. The quantity of a cell-associated fluorescence following phagocytic uptake is monitored using flow cytometry analysis according essentially to the method described by Sallusto, F. et al. (1995), J. Exp. Med., 182:389-400, which is herein incorporated by reference in its entirety. In these tests, the background values have been subtracted from those of the experimental samples and dead cells have been excluded from the data using propidium iodide exclusion.

Each of Figures 7 and 8 shows an overlay of the log fluorescence versus cell number for the PBS control (purple), the Product R treatment (green) and the background Dextran binding to cells (black). The purple curves (PBS control) are substantially overlapped with the green curves (Product R) at each time point, indicating that Product R does not inhibit 5 phagocytosis of human monocytic cells.

Other biological functions of Product R: Some of other known biological functions of Product R have been described in U.S. Patent Nos. 5,807,840, 5,807,839 and 5,902,786; U.S. patent application Serial Nos. 08/838,077, 08/838,069, 08/835,793, 08/835,794, 08/833,950, 08/837,992, 08/837,988, 08/838,070, 08/834,190, 08/835,791, 08/838,134, 10 08/839,651, 08/835,796, 08/964,250, 08/964,427, 08/923,516, 08/923,343, 08/922,888, 09/189,172, 09/007,565, 09/316,624, 09/316,374, 09/257,739 and the publication by Hirschman et al., J. Investig. Med. 1996; 44:347-351. These patents, patent applications and publication are herein incorporated by references in their entireties.

Conclusions

15 It is thus determined that the composition of Product R prepared according to the present described methods comprises nucleotides and peptides having molecular weights not more than 14 KDa, primarily not more than 8 KDa. The peptide components of Product R are unevenly distributed and typically located at two major silverstainable bands having molecular weights of 4.3 KDa, 5.2 KDa and a minor band of 7.6 KDa.

The UV absorption spectrum of Product R typically shows a maximum absorption at 260 nm and a trough at 235 nm, and the characteristic ratios of the absorbance at 260 nm over absorbance at 280 nm is 1.998 and at 260 nm over 230 nm is 1.359.

5 The HPLC profile of Product R comprises fractions of A, B, C, D, E, F, G, H, I, J, K, L and M as shown in Figure 2.

The BioGel P-2 Gel filtration profile of Product R comprises fractions of I, Ia, II, IIa, IIb, III, IIIa, IV and IVa as shown in Figure 3.

Comparison Between The Conventional Composition Of Reticulose® And Product R

10 The composition of Product R as made according to the teachings of the present invention is compared with the conventional composition of RETICULOSE® with respect to their molecular weights (MW) and ultraviolet (UV) absorbancies (A) at wavelength of 230 nm, 260 nm and 280 nm, as shown in TABLE IV. While the components having molecular weights below 15 KDa of RETICULOSE® have been reported to inhibit the phagocytosis, the present application
15 demonstrates that Product R does not inhibit the phagocytosis.

TABLE IV

	MW	UV	I/PH*		
		A _{260/280}	A _{260/230}		
5					
Product R	< 14 KDa	1.998	1.359	No	
10	RETICULOSE®	1 - 25 KDa	2.839	1.198	Yes

*inhibition of phagocytosis by molecules having molecular weight below 15 KDa

Thus, Product R differs substantially from RETICULOSE® in their composition
15 and biological functions.

TABLE V is a comparison between the relative amounts of the starting materials used for the preparations of the present therapeutic composition Product R and the conventional composition RETICULOSE®.

TABLE V

	<u>STARTING MATERIALS FOR INITIAL REACTION IN TEN LITERS</u>	RETICULOSE®	Product R
25	casein	250 grams	140 grams
	beef peptone	150 grams	68.4 grams
30	serum albumin	15 grams	13 grams
	RNA	80 grams	88 grams
	NaOH	75 grams	66 grams

About 221 grams proteins are used in the initial reaction for the preparation of Product R, while about 415 grams for the preparation of RETICULOSE®. Thus, the initial protein concentration for the RETICULOSE® preparation is twice as much as that for the Product R preparation.

5

The following example only serves as an illustration of the process of making Product R and should not be construed as a limitation of the present invention.

Example

Suspend about 35.0 g of casein, about 17.1 g of beef peptone, about 22.0 g of
10 nucleic acid (yeast RNA), about 3.25 g bovine serum albumin in about 2.5 liters of water for injection USP at about 3 to 7 °C in a suitable container and gently stir until all the ingredients have been properly wet. Carefully add while stirring about 16.5 g of sodium hydroxide (reagent grade ACS) and continue stirring until sodium hydroxide completely dissolved. Autoclave at about 9 lbs. pressure and 200 - 230 °F for a period of time until RNA is completely digested, for
15 example, about 4 hours. At the end of the period, the autoclave is stopped and the reaction flask and contents are permitted to slowly cool to ambient temperature. Then cool for at least six hours at about 3-8 °C. The resulting solution is filtered through 2 micron and 0.45 micron filters using inert gas such as nitrogen or argon at low pressure (1-6 psi). In a similar manner the solution is filtered again through 0.2 micron pyrogen retention filters. The resulting filtrate is sampled and
20 assayed for total nitrogen. A calculation is then performed to determine the quantity of cooled water for injection to be added to the filtrate to yield a diluted filtrate with a nitrogen content

between about 165-210 mg/100ml, the final volume is approximately 5 liters. The pH is then adjusted with either concentrated HCl (reagent grade ACS) or 1.0 normal NaOH to about 7.3 - 7.6 range. The diluted solution is then filtered again through 0.2 micron filters with inert gas at low pressure. The final filtrate is then filled and sealed into 2 ml glass ampules while in an inert gas atmosphere. The ampules are collected and autoclaved for final sterilization at 240 °F and 14-16 pounds pressure for about 30 minutes. Following the sterilization cycle, the ampules with Product R are cooled and washed.

All quantities are subject to plus or minus 15% variation for pH, volume, and analytical adjustments.

Thus, while there have shown and described and pointed out fundamental novel features of the invention as applied to a preferred embodiment thereof, it will be understood that various omissions and substitutions and changes in the form and details of the devices illustrated, and in their operation, may be made by those skilled in the art without departing from the spirit of the invention. For example, it is expressly intended that all combinations of those elements and/or method steps which perform substantially the same function in substantially the same way to achieve the same results are within the scope of the invention. Moreover, it should be recognized that structures and/or elements and/or method steps shown and/or described in connection with any disclosed form or embodiment of the invention may be incorporated in any other disclosed or described or suggested form or embodiment as a general matter of design choice. It is the intention, therefore, to be limited only as indicated by the scope of the claims appended hereto.

CLAIMS

We claim:

1 1. A peptide nucleic acid composition that absorbs light at wavelengths
2 230nm, 260nm and 280nm so as to result in 260nm/280nm absorption ratio of about 1.998 and
3 260nm/230nm absorption ratio of about 1.359, comprising molecules of nucleotides resulting
4 from a plant RNA and peptides resulting from a mixture of casein, beef peptone and bovine
5 serum albumin, said molecules having non-uniformly distributed molecular weights.

1 2. The composition of claim 1, wherein said nucleotides are mono-
2 nucleotides.

1 3. The composition of claim 1, wherein said molecules have non-uniformly
2 distributed molecular weights in a range from zero to substantially not more than 14 KDa.

1 4. The composition of claim 1, wherein said molecules have non-uniformly
2 distributed molecular weights in a range from zero to substantially not more than 8 KDa.

1 5. The composition of claim 1, wherein said molecules have substantial
2 concentrations at molecular weights of substantially 5.2 KDa and 4.3 KDa.

1 6. A method for preparing a peptide nucleic acid composition that absorbs
2 light at wavelengths 230nm, 260nm and 280nm so as to result in 260nm/280nm absorption ratio
3 of about 1.998 and 260nm/230nm absorption ratio of about 1.359, said composition containing

4 molecules of nucleotides and peptides having non-uniformly distributed molecular weights,
5 comprising the steps of:

6 a. forming a mixture including a protein combination consisting of casein,
7 beef peptone and bovine serum albumin, a plant RNA and a base in water, wherein the ratio of
8 said protein combination to said water is in a range from about 1.5 / 100 to about 2.5 / 100 by
9 weight;

10 b. processing said mixture at an elevated temperature and an elevated pressure
11 so as to form a solution and insoluble elements;

12 c. removing said insoluble elements;
13 d. diluting said solution with water; and
14 e. after performing steps b, c and d, adjusting the pH of said solution to a
15 physiologically acceptable pH.

16
17 7. The method of claim 6, wherein the ratio of said protein combination to
18 said water is about 2.2 / 100 by weight.

1 8. The method of claim 6, wherein said nucleotides are mono-nucleotides.

1 9. The method of claim 6, wherein said molecules have non-uniformly
2 distributed molecular weights in a range from zero to substantially not more than 14 KDa.

1 10. The method of claim 6, wherein said molecules have non-uniformly
2 distributed molecular weights in a range from zero to substantially not more than 8 KDa.


3 11. The method of claim 6, wherein said molecules have substantial
4 concentrations at molecular weights of substantially 5.2 KDa and 4.3 KDa.

ABSTRACT OF THE DISCLOSURE

Product R, a novel therapeutic composition for treating viral infections and stimulating the immune system, comprises nucleotides and peptides that have molecular weights not more than 14 KDa and substantially not more than 8 KDa. The composition has a light absorption spectrum with typical absorption ratios of 1.998 at 260nm/280nm and 1.359 at 5 260nm/230nm.

Figure 1

Product R
ULTRAVIOLET SPECTRUM OF PEPTIDE NUCLEIC ACID
PREPARATION




Product R

The spectrum was obtained on a 1:100 dilution of peptide nucleic acid in distilled water and was recorded on a Shimadzu Model UV-1201 UV-VIS Spectrophotometer. The spectrum was recorded between 220-320 nm and shows an absorption maximum at 260 nm with a trough at 235 nm.

$$A_{260/280} = 1.998; A_{260/230} = 1.359$$

Figure 2



HPLC ANALYSIS

Reverse phase HPLC chromatogram using A YMC-ODS-AQ column, 250 x 10 mm ID; isocratic elution with 0.1M acetic acid/triethylamine, pH 4.8 mobile phase, 8uL injection at a column temperature of 30°C. The separation was carried out on a Hewlett Packard 1100 binary pump HPLC system with multi-wavelength diode array detector, measured at 260 nm.

Figure 3

Product R
Fractionation of ~~Recombinant Human~~ ~~Human~~ ~~4500000~~ by BioGel P-2 Column
Filtration Column- 2.6cm X 55cm
Elution Buffer- 0.1XPBS (Ca⁺⁺ & Mg⁺⁺ free)
Flow Rate- 0.5ml/min





Figure 4.



SDS-Polyacrylamide gel (16%) electrophoresis of Reticulose and Peak fractions from BioGel P2 column : Retinol: ^{Product R} and Peak I fraction show two strong silver stained bands, later fractions show no band. ->, indicates gel start point. Eluted fractions were ten fold concentrated, 2 μ l of Reticulose and 1 μ l of each concentrated fraction were used in the gel.




Figure 5. SDS-PAGE Profile.




Figure 6. Sensitivity of Product R to Catabolic Enzymes

->, starting point of gel


Panel a, lane 1, Product R in Trypsin reaction buffer;
 lane 2, Product R treated with Trypsin (0.05 mg/ml);
 lane 3, Product R treated with Trypsin (0.025mg/ml);
 lane 4, Product R in Chymotrypsin reaction buffer;
 lane 5, Product R treated with Chymotrypsin (0.05mg/ml); and
 lane 6, Product R treated with Chymotrypsin (0.025mg/ml).

Panel b, lane 1, Product R in Proteinase K reaction buffer; and
 lane 2, Product R treated with Proteinase K (0.8mg/ml).

Panel c, lane 1, Product R treated with Ribonuclease A (0.5mg/ml);
 lane 2, Product R treated with Ribonuclease A (1.0mg/ml);
 lane 3, Product R treated with Alkaline Phosphatase (100units/ml);
 lane 4, Product R treated with Alkaline Phosphatase (200units/ml);
 lane 5, Untreated Product R;
 lane 6, Product R treated with N-glycosidase F (20 units/ml); and
 lane 7, Product R treated with N-glycosidase F (50 units/ml).

Note: All bands other than the 5.2 KDa and the 4.3 KDa bands represent either the enzymes themselves or the fragments of those enzymes.

Figure 7. Effects of Product R upon phagocytosis of Dextran-FITC by U937 cells after 24 hr drug treatment




Key:

purple = + PBS
 green = + Product R
 black = 0 min control

Figure 8. Effects of Product R upon phagocytosis of Dextran-Bodipy FL after an 8 day drug treatment

Drug treatment: 8 days +/- Product R



Key:

- purple = + PBS
- green = + Product R
- black = 0 min control



DECLARATION AND POWER OF ATTORNEY FOR CIP PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

PREPARATION OF A THERAPEUTIC COMPOSITION

the specification of which is attached hereto unless the following box is checked:

was filed on October 22, 1996 as United States Application Number or PCT International Application Number 08/735,236 and was amended on (if applicable).

I hereby state that this application in part discloses and claims subject material disclosed in my earlier-filed pending application Serial No. 08/735,236 filed October 22, 1996.

I hereby state that I reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. § 1.56.

I also acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37 CFR 1.63(d), which occurred between the filing date of the prior application and the filing date of the continuation-in-part application, if this is a continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT international application having a filing date before that of the application on which priority is claimed:

Prior Foreign Application:

Country:

Appln. No.:

Filed:

Priority Not Claimed:

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below.

Application No.: **Filing Date:**

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT international application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

Appln No.: 08/735,236 Filing Date: October 22, 1996 Status: pending

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

MYRON COHEN, Reg. No. 17,358; THOMAS C. PONTANI, Reg. No. 29,763; LANCE J. LIEBERMAN, Reg. No. 28,437; MARTIN B. PAVANE, Reg. No. 28,337; MICHAEL C. STUART, Reg. No. 35,698; KLAUS P. STOFFEL, Reg. No. 31,668; EDWARD M. WEISZ, Reg. No. 37,257; CHI K. ENG, Reg. No. 38,870; JULIA S. KIM, Reg. No. 36,567; VINCENT M. FAZZARI, Reg. No. 26,879; ALFRED W. FROEBRICH, Reg. No. 38,887; ANDRES N. MADRID, Reg. No. 40,710; KENT H. CHENG, Reg. No. 33,849; GEORGE WANG, Reg. No. 41,419; JEFFREY M. NAVON, Reg. No. 32,711 and JOHN G. TUTUNJIAN, Reg. No. 39,405.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Address all telephone calls to Myron Cohen, Esq. at telephone No. (212) 687-2770.

Address all correspondence to:

Myron Cohen, Esq.
Cohen, Pontani, Lieberman & Pavane
551 Fifth Avenue, Suite 1210
New York, New York 10176

Full Name of Sole or First Inventor: **Bernard FRIEDLAND**

Inventor's signature: Bernard Friedland

Dated: JUNE 24, 1999
Month/Day/Year

Residence: **P.O. Box 3947
Sarasota, Florida 34230**

Citizenship: **United States Of America**

Post Office Address: **P.O. Box 3947
Sarasota, Florida 34230**

Full Name of Second Joint Inventor: **Shalom Z. HIRSCHMAN**

Inventor's signature: _____

Dated: _____
Month/Day/Year

Residence: **5240 Blackstone Ave.
Riverdale, NY 10471**

Citizenship: **United States of America**

Post Office Address: **5240 Blackstone Ave.
Riverdale, NY 10471**

Full Name of Sole or First Inventor: Bernard FRIEDLAND

Inventor's signature: _____

Dated: _____
Month/Day/Year

Residence: P.O. Box 3947
Sarasota, Florida 34230

Citizenship: United States Of America

Post Office Address: P.O. Box 3947
Sarasota, Florida 34230

Full Name of Second Joint Inventor: Shalom Z. HIRSCHMAN

Inventor's signature: Shalom Z. Hirschman

Dated: June 25, 1999
Month/Day/Year

Residence: 5240 Blackstone Ave.
Riverdale, NY 10471

Citizenship: United States of America

Post Office Address: 5240 Blackstone Ave.
Riverdale, NY 10471

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.